Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation

Ibrutinib, a clinically approved irreversible BTK kinase inhibitor for Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL) etc, has been reported to be potent against EGFR mutant kinase and currently being evaluated in clinic for Non Small Cell Lung Cancer (NSCLC). Through EGFR wt/muta...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncotarget
Auteurs principaux: Wang, Aoli, Yan, Xiao-E, Wu, Hong, Wang, Wenchao, Hu, Chen, Chen, Cheng, Zhao, Zheng, Zhao, Peng, Li, Xixiang, Wang, Li, Wang, Beilei, Ye, Zi, Wang, Jinhua, Wang, Chu, Zhang, Wei, Gray, Nathanael S., Weisberg, Ellen L., Chen, Liang, Liu, Jing, Yun, Cai-Hong, Liu, Qingsong
Format: Artigo
Langue:Inglês
Publié: Impact Journals LLC 2016
Sujets:
Research Paper
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5342513/
https://ncbi.nlm.nih.gov/pubmed/27626175
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.11951
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires